Effect of oral soft gel containing lemon essential oil and Xenical capsule in treatment of obesity

Effect of oral soft gel containing lemon essential oil and Xenical capsule on weight in subjects with overweight and obesity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306225623N9

Enrollment

105

Registered

2013-06-30

Start date

2013-07-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity. Obesity, unspecified

Interventions

Intervention 1: Intervention group: Oral soft gel containing lemon essential oil, 100 mg, three times a day, for 8 weeks orally. Intervention 2: Intervention group: Xenical capsule, 120 mg, three time

Treatment - Drugs

Intervention group: Oral soft gel containing lemon essential oil, 100 mg, three times a day, for 8 weeks orally.

Intervention group: Xenical capsule, 120 mg, three times a day, for 8 weeks orally.

Control group: Placebo capsule, three times a day, for 8 weeks orally.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Subjects aged 18-50 years; BMI=25. Exclusion Criteria: Individuals with neoplastic; cardiovascular disorders; malabsorptive disorders; current or previous (within the last 6 months) use of hormonal; anti-obesity medications.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: Baseline and End-of-trial. Method of measurement: Scale.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;T3. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;T4. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;TSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.	—

Measure

Time frame

Weight. Timepoint: Baseline and End-of-trial. Method of measurement: Scale.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;T3. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;T4. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;TSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026